The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the data from Paraguay’s Ministry of Health on the one shot Russian Sputnik Light vaccine (the first component of the Sputnik V vaccine) demonstrating high safety profile and a 93.5% efficacy, as reported during the ongoing vaccination campaign in the country.
The one shot Sputnik Light vaccine has proven to be highly effective against COVID among more than 320,000 subjects who had received the vaccine based on the data collected by July 30, 2021. The data also indicates a high safety profile of Sputnik Light:
- No serious adverse events associated with vaccination;
- No deaths related to the vaccination;
- No cerebral vein thrombosis (CVT) cases after vaccination;
- No Guillain-Barre syndrome (GBS) cases after vaccination;
- No capillary leak syndrome cases after vaccination;
- No cases of myocarditis or pericarditis reported.
Thanks to its safety and efficacy, single-component Sputnik Light vaccine is now both used on standalone basis and also studied in combination with vaccines from other producers in a number of countries.
The heterogeneous boosting approach (“vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus, RDIF took the lead in initiating partnerships with other vaccine producers to conduct joint studies of a combination of the first component of Sputnik V with foreign vaccines.
In particular, initial safety results of the world’s first study of a combination between Sputnik Light and the AstraZeneca vaccine in Azerbaijan demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination.
Also RDIF, Ministry of Health of Argentina, Ministry of Science of Argentina and CONICET are conducting a study for the evaluation of the immune response and safety of heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm and Moderna in the city and province of Buenos Aires, as well as San Luis, Cordoba and La Rioja provinces. The results of the study will be published in a peer-reviewed medical journal.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
The one shot Sputnik Light vaccine enables authorities of Paraguay to speed up the vaccination of the population and accelerate the creation of herd immunity. As demonstrated by data from the Ministry of Health of Paraguay, as well as and a number of other countries around the world, Sputnik Light has a high safety profile and one of the best efficacy numbers as compared to many two shot vaccines.